Michael Gelband’s Cidara Therapeutics CDTX Stock Holding History

Michael Gelband’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,442	Closed	-$981K	–	1602
2025 Q4	$981K	Sell	4,442 -2,328	-34%	-$376K	0.01%	1002
2025 Q3	$648K	Buy	+6,770	New	+$432K	0.01%	1108
2022 Q1	–	Sell	-577	Closed	-$15K	–	2233
2021 Q4	$15K	Buy	577 +5	+0.9%	+$156	﹤0.01%	2093
2021 Q3	$26K	Sell	572 -704	-55%	-$26.7K	﹤0.01%	2009
2021 Q2	$52K	Buy	+1,276	New	+$54K	﹤0.01%	2218
2020 Q2	–	Sell	-812	Closed	-$40K	–	1792
2020 Q1	$40K	Buy	+812	New	+$48.7K	﹤0.01%	977

Michael Gelband's CDTX Position: Q1 2026 in Review

Michael Gelband sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 4,442 shares — an estimated $981K sold.

Michael Gelband first reported a position in CDTX in Q1 2020 and held it in 6 quarters. The position peaked at $981K in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Michael Gelband reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Michael Gelband sold 4,442 Cidara Therapeutics shares in Q1 2026, an estimated $981K.
Michael Gelband first reported a position in Cidara Therapeutics in Q1 2020 and held it in 6 quarters.
Michael Gelband's Cidara Therapeutics position peaked at $981K in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.